Drugs / GSK933776
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02033668 | Jan → Jul 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01424436 | May 2010 → Dec 2011 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00459550 | Mar 2007 → May 2011 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01342926 | Jun 2011 → Apr 2016 | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK933776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01424436 ↗ |
| Modality | Monoclonal antibody | “Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776” PMID 25789616 ↗ Mar 2015 |
| Route | Intravenous | “intravenous GSK933776 0.001-6 mg/kg” PMID 25789616 ↗ Mar 2015 |
| Target | APP | “Amyloid-beta A4 protein binding agent” CHEMBL2109300 ↗ |